Celecoxib with immunotherapy for bile duct cancer
Part of Cancer clinical trials.
This trial tests whether adding celecoxib (an anti-inflammatory pill) to pembrolizumab (an immunotherapy) and chemotherapy helps treat intrahepatic cholangiocarcinoma—a type of bile duct cancer that cannot be surgically removed. The goal is to see if this combination works better than the standard two-drug approach.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have intrahepatic cholangiocarcinoma (bile duct cancer inside the liver) confirmed by biopsy or tissue sample
- Your cancer cannot be removed by surgery and is locally advanced, recurrent, or has spread to other parts of your body
- You have never received chemotherapy or immunotherapy for advanced cancer before
- You have at least one tumor that can be measured on imaging scans
- Your overall health is good enough for treatment (ECOG score 0–1, meaning you can do most daily activities)
- Your liver and kidney function and blood counts meet protocol requirements
- If your bile ducts are blocked, they must be unblocked and you must be stable before starting
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of targeted therapy, immunotherapy, and a liver-directed procedure (like chemoembolization) versus a standard chemotherapy cocktail for a type of bile duct cancer that is confined to the liver. It aims to see if the new combo can help patients live longer or slow the cancer down.
This trial tests whether adding an immunotherapy drug (toripalimab) to standard chemotherapy before surgery can improve outcomes for people with intrahepatic cholangiocarcinoma that can be surgically removed. It's for patients who haven't had prior treatment for their cancer and are in good overall health.
This trial tests a combination of chemotherapy directly to the liver, a targeted therapy pill, and an immunotherapy drug for people with advanced bile duct or gallbladder cancer that cannot be surgically removed. The goal is to see if this triple therapy can shrink or control the cancer.
This study tests additional treatment given after surgery to remove high-risk intrahepatic cholangiocarcinoma (a type of bile duct cancer). The goal is to reduce the chance the cancer comes back and improve survival in patients whose tumors had concerning features.
This trial tests a new combination of drugs for people with advanced bile duct cancer that cannot be removed by surgery. Combining immunotherapy with chemotherapy may help shrink tumors and slow the cancer's growth.
This trial tests a combination of chemotherapy (gemcitabine and cisplatin) with the targeted therapy lenvatinib and the immunotherapy adebrelimab for people with advanced bile duct cancer that cannot be removed by surgery. It aims to see if this combination works better than standard treatments.
Hear when a new Intrahepatic Cholangiocarcinoma (Icc) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.